Aduro Biotech has announced that  Hans van Eenennaam has been promoted to executive vice president antibody research and site head of Aduro Biotech Europe. Prior to its acquisition by Aduro in 2015, Hans served as chief operating officer of BioNovion, a company he co-founded in 2011 to focus on the development of innovative therapeutic antibodies in the field of immune oncology. He currently sits on the board of directors for Lygature, a non-profit organization that independently enables public-private partnerships between large corporates, smaller companies and academia and helps med-tech and pharma professionals to work together.